| 17.8367 0.067 (0.38%) | 04-10 12:27 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 20.95 | 1-year : | 24.47 |
| Resists | First : | 17.94 | Second : | 20.95 |
| Pivot price | 16.6 |
|||
| Supports | First : | 16.06 | Second : | 14.89 |
| MAs | MA(5) : | 17.25 |
MA(20) : | 16.71 |
| MA(100) : | 17.66  |
MA(250) : | 18.29 |
|
| MACD | MACD : | 0 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 90.9 |
D(3) : | 82.7 |
| RSI | RSI(14): 58.7 |
|||
| 52-week | High : | 22.5 | Low : | 14.89 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ MDWD ] has closed below upper band by 12.3%. Bollinger Bands are 55.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 17.96 - 18.03 | 18.03 - 18.1 |
| Low: | 16.84 - 16.92 | 16.92 - 17 |
| Close: | 17.64 - 17.76 | 17.76 - 17.89 |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Wed, 08 Apr 2026
MediWound to Present New EscharEx® Data at Leading Wound Care Conferences - Sahm
Tue, 07 Apr 2026
MDWD SEC Filings - Mediwound 10-K, 10-Q, 8-K Forms - Stock Titan
Tue, 07 Apr 2026
From burns to ulcers: new MediWound EscharEx data heads to 3 meetings - Stock Titan
Thu, 02 Apr 2026
BARDA’s up-to-$197M NexoBrid contract highlighted by MediWound (MDWD) - Stock Titan
Thu, 02 Apr 2026
MediWound and Vericel Secure Up to $197 Million BARDA Contract for NexoBrid® Procurement and Development - Quiver Quantitative
Wed, 25 Mar 2026
MediWound (MDWD) director details options, RSU and share holdings - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 13 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 15.8 (%) |
| Held by Institutions | 56.9 (%) |
| Shares Short | 1,390 (K) |
| Shares Short P.Month | 1,340 (K) |
| EPS | -2.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.4 |
| Profit Margin | -140.9 % |
| Operating Margin | -417.8 % |
| Return on Assets (ttm) | -19.8 % |
| Return on Equity (ttm) | -63.9 % |
| Qtrly Rev. Growth | -68 % |
| Gross Profit (p.s.) | 0.25 |
| Sales Per Share | 1.31 |
| EBITDA (p.s.) | -1.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -16 (M) |
| PE Ratio | -8.45 |
| PEG Ratio | 0 |
| Price to Book value | 5.21 |
| Price to Sales | 13.44 |
| Price to Cash Flow | -14.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|